Early-Onset Pancreatic Cancer Shows Aggressive Molecular Biology : Br J Surg | May 2026

Introduction

The global rise in early-onset gastrointestinal malignancies has become a major oncologic concern, with pancreatic ductal adenocarcinoma (PDAC) increasingly being diagnosed in patients younger than 50 years. Although younger patients are generally presumed to tolerate aggressive multimodality treatment better, the biological behavior of early-onset pancreatic cancer (EOPC) remains poorly understood.

Problem Statement

Existing studies evaluating outcomes in EOPC have produced conflicting results, and the molecular mechanisms underlying disease aggressiveness in younger patients remain unclear. Whether EOPC differs biologically from late-onset PDAC has important implications for prognosis, surveillance and therapeutic decision-making.

Summary

This large multicenter translational study demonstrated that surgically resected EOPC is associated with significantly earlier postoperative recurrence and more aggressive molecular characteristics compared with late-onset PDAC. Despite receiving adjuvant chemotherapy more frequently and completing treatment more often than older patients, individuals with EOPC experienced shorter disease-free survival and remained at increased risk of recurrence after resection. Importantly, these poorer outcomes could not be explained by conventional clinicopathological factors such as tumor stage, nodal burden, margin status or differentiation grade. Transcriptomic analysis revealed enrichment of squamous (basal-like) molecular subtype signatures in EOPC, including increased expression of aggressive genes such as S100A2, TP63 and MYC-related proliferative pathways, alongside downregulation of GATA6, a marker associated with the more favorable classical pancreatic subtype. Gene programs linked to cell proliferation, squamous differentiation, inflammation and metabolic reprogramming were significantly enriched in younger patients, supporting a biologically aggressive phenotype. Additionally, immune-related gene pathways appeared relatively suppressed in EOPC, although major differences in immune cell infiltration were not definitively demonstrated. Germline mutations were not more common in younger patients, suggesting that inherited predisposition alone does not explain disease biology. Collectively, the findings challenge the assumption that younger age predicts favorable pancreatic cancer outcomes and instead support EOPC as a distinct high-risk biological subtype that may require intensified surveillance, earlier systemic therapy optimization and prioritization for biomarker-driven clinical trials.